Maxcyte, Inc.
MXCT- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001287098
No open-market purchases or sales by Maxcyte, Inc. insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $78.0M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −7 vs. previous quarter
- 122
- 13F valueReported value at the end of Q2 2026
- $78.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding MXCT, Q2 2026
No superinvestor reported holding MXCT at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Maxcyte, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 (view filing) | Mar 17 | 2 days | Swirsky Douglas JCHIEF FINANCIAL OFFICER | SSale | −10.1K | $0.82 | −$8.32K | −6.3%151.7K after | |
| Aug 27, 2025 (view filing) | Jun 25 | 63 daysLate | Hemrajani RekhaDirector | SSale | −10.7K | $2.09 | −$22.3K | −21.1%39.9K after | 10b5-1 |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Swirsky Douglas JCHIEF FINANCIAL OFFICER | PPurchase | +50.0K | $1.29 | +$64.5K | +44.7%161.8K after | |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Masoud MaherPresident and CEO | PPurchase | +75.0K | $1.37 | +$102.8K | +75.0%175.0K after | |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Erck Stanley CDirector | PPurchase | +100.0K | $1.37 | +$137.0K | +33.5%398.3K after | |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Douglas RichardDirector | PPurchase | +80.0K | $1.39 | +$111.2K | +53.1%230.6K after | |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Brooke William WDirector | PPurchase | +50.0K | $1.29 | +$64.5K | +49.6%150.9K after | |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | Soleymannezhad AliChief Commercial Officer | SSale | −1.21K | $3.18 | −$3.85K | −2.0%59.4K after | |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | Sandoval David I.GENERAL COUNSEL | SSale | −353 | $3.18 | −$1.12K | −0.5%64.2K after | |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | Swirsky Douglas JCHIEF FINANCIAL OFFICER | SSale | −6.94K | $3.18 | −$22.1K | −5.8%111.8K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Maxcyte, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Capricorn Fund Managers Ltd | 8,200,000 | $10.1M | 0.81% | 00.0% | Unchanged |
| Vitruvian Partners LLP | 5,043,356 | $6.20M | 3.09% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 4,031,284 | $4.96M | 0.00% | +49,468+1.2% | Added |
| Morgan Stanley | 3,694,049 | $4.54M | 0.00% | +5,918+0.2% | Added |
| Mudita Advisors LLP | 3,370,689 | $4.15M | 0.86% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,060,960 | $3.76M | 0.00% | −5,737,513−65.2% | Reduced |
| Brooklands Fund Management Ltd | 2,848,083 | $3.67M | 2.88% | +658,063+30.0% | Added |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2,773,554 | $3.41M | 0.00% | 00.0% | Unchanged |
| Cadian Capital Management, LP | 2,201,166 | $2.71M | 0.20% | +478,224+27.8% | Added |
| Peapod Lane Capital LLC | 2,125,752 | $2.61M | 1.76% | +793,559+59.6% | Added |